Clopidogrel Bisulfate Tablet, Film Coated
Product Images NDC 63187-639

Product Visual Gallery

This gallery contains 10 technical images submitted to the FDA as part of the official labeling for Clopidogrel Bisulfate (NDC 63187-639). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Proficient Rx Lp, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Figure1 (Clopidogrel Fig1)

A horizontal error bar chart showing the effect of co-administered proton pump inhibitors (PPIs) on active metabolite AUC, with mean values and 90% confidence intervals. The PPIs listed are Dexlansoprazole 60 mg, Lansoprazole 30 mg, Pantoprazole 80 mg, and Omeprazole 80 mg, with corresponding effects displayed on a scale ranging approximately from 0.4 to 1.4.*

FDA Label Image

Figure3 (Clopidogrel Fig2)

A line graph depicting cumulative event rates (%) for cardiovascular death, myocardial infarction, and stroke over 12 months of follow-up. Two curves compare Placebo (+ aspirin) and Clopidogrel bisulfate (+ aspirin), showing lower event rates with Clopidogrel bisulfate. The graph includes a statistical significance indication (P=0.00009).*

FDA Label Image

Figure3 (Clopidogrel Fig3)

A forest plot chart comparing percent events for Clopidogrel (with aspirin) versus placebo (with aspirin) across various baseline characteristics, concomitant medications, and clinical subgroups such as age, gender, race, diabetes, previous myocardial infarction, stroke, and use of other drugs. The chart shows hazard ratios with confidence intervals for each subgroup, illustrating relative treatment effects of Clopidogrel versus placebo.*

FDA Label Image

Figure4 (Clopidogrel Fig4)

A line graph showing the percentage of deaths before first discharge over 28 days since randomization, comparing placebo and Clopidogrel. The graph indicates 1845 deaths (8.1%) with placebo and 1726 deaths (7.5%) with Clopidogrel, noting a 7% proportional risk reduction (p = 0.03).*

FDA Label Image

Figure5 (Clopidogrel Fig5)

A Kaplan-Meier survival curve graph showing the percentage of subjects with death, reinfarction, or stroke before final discharge over time in days since randomization (up to 28 days). The graph compares outcomes for placebo and clopidogrel groups, including statistics on proportional risk reduction.*

FDA Label Image

Figure6 (Clopidogrel Fig6)

A forest plot chart depicting baseline categorization of events (%) comparing Clopidogrel (22,961 participants) and placebo (22,891 participants) groups. Variables include sex, age, hours since onset, systolic blood pressure, heart rate, fibrinolytic agent use, prognostic index, and metoprolol allocation. The plot shows odds ratios and confidence intervals, with a summary weighted average indicating a proportional reduction of 9% (p=0.002).*

FDA Label Image

Figure7 (Clopidogrel Fig7)

A forest plot chart comparing Clopidogrel bisulfate with placebo in various categories, including Killip class, previous myocardial infarction, and infarct location. The chart displays event percentages for each group, odds ratios with confidence intervals, and heterogeneity test results indicating proportional reduction of 9% in events with Clopidogrel.*

FDA Label Image

Figure8 (Clopidogrel Fig8)

A line graph titled 'Fatal or Non-Fatal Vascular Events' showing cumulative event rates over 36 months of follow-up. It compares two lines labeled 'Aspirin' and 'Clopidogrel,' with event rates increasing over time. The graph includes a p-value of 0.045, indicating statistical comparison.*

FDA Label Image

63187-639-30 (Clopidogrel Fig9)

Label for Clopidogrel 75 mg tablets, film-coated, round, biconvex, pink tablets with imprint SG and 124. Contains 30 tablets per bottle. Manufactured by ScieGen Pharmaceuticals, Inc., Hauppauge, NY, and relabeled by Proficient Rx LP, Thousand Oaks, CA. NDC 63187-639-30. Includes storage instructions and medication guide dispensing note.*

FDA Label Image

Structure (Clopidogrel Str)

Chemical structure of Clopidogrel bisulfate, showing its molecular arrangement including thienopyridine and chlorophenyl groups with the bisulfate component indicated.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.